Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IntoCell DLL3 ADC
- Development stage
- Preclinical
- Lead developer
- IntoCell
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
IntoCell DLL3 ADC is a preclinical-stage antibody-drug conjugate (ADC) designed to target delta-like ligand 3 (DLL3), a protein that is highly expressed in neuroendocrine-derived tumors, such as small cell lung cancer (SCLC) and neuroendocrine prostate cancer (NEPC), while having minimal expression in normal tissues. The therapeutic utilizes IntoCell's proprietary Ortho-Hydroxy PAS (OHPAS) linker technology to conjugate a cytotoxic payload to a DLL3-specific monoclonal antibody. This platform is engineered to maintain high stability in systemic circulation and ensure the efficient, site-specific release of the payload upon internalization into the target cancer cell. By delivering a potent cytotoxin directly to DLL3-expressing cells, the drug aims to maximize anti-tumor activity while reducing off-target toxicity associated with conventional chemotherapy.
- Other names
- delta-like ligand 3 antibody-drug conjugateIntoCell DLL3-targeted ADC
02
Targets
DLL3 (Delta-like ligand 3)
Beyond the preview
Go deeper on IntoCell DLL3 ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IntoCell DLL3 ADC.